Gut bacteria capsules may shield heart surgery patients from organ damage

NCT ID NCT04444362

ENROLLING_BY_INVITATION Disease control Sponsor: Nanjing Medical University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether giving patients capsules containing gut bacteria (called Probacine) before and after heart surgery can reduce gut injury and organ failure. Researchers will enroll 500 adults undergoing cardiovascular surgery. The goal is to see if changing the gut microbiome can improve recovery and lower death rates.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Intestinal Microbiota Transplant (IMT) Capsules
What this could lead to: If it works, this could point toward a simple way to protect the gut and organs after heart surgery, reducing complications.
What could go wrong: This is an early-stage trial with no phase designation, so results are uncertain. The intervention involves transplanting gut bacteria, which carries unknown risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIOPULMONARY BYPASS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiovascular disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIOPULMONARY BYPASS CARDIOVASCULAR DISEASE

Contacts and locations

Locations

Beijing Anzhen Hospital

Beijing, Beijing Municipality, China
Shanghai East Hospital, Tongji University

Shanghai, China
The First Affiliated Hospital of Guangzhou Medical University

Guangzhou, Guangdong, China
The First Affiliated Hospital of Nanjing Medical University

Nanjing, Jiangsu, 210029, China
West China Hospital of Sichuan University

Chengdu, Sichuan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.